Investigational drug · Phase 2
CMND-100
Also called: MEAI
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alcohol Use Disorder.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 31, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "CMND-100"
First trial start
2025
Apr 30, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CMND-100", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alcohol Use Disorder
Approved drugs for the same conditions: Alcohol dependence · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "CMND-100" as an intervention, largest first.
Clearmind Medicine Inc.Industry
NCT05913752 · 84 participants (planned) · Start Apr 30, 2025 · Primary completion Dec 31, 2026
Drug: CMND-100 · For: Alcohol Use Disorder
Sites: New Haven, Connecticut; Baltimore, Maryland; Jerusalem, Israel · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The entropic view of aging: from thermodynamics to biology.
Wu Z, Ma S, Wang S, et al. · Life Med 2026
- Methanol Leaf Extract of Azadirachta Indica Attenuates Lead Acetate-Induced Cardiorenal Toxicity in Rats.
AdeyeOluwa T, Oyagbemi A, Adedapo A, et al. · Niger J Physiol Sci 2025
- Role of Composition and Temperature in Shaping the Structural and Optical Properties of Iodide-Based Hybrid Perovskite Thin Films Produced by PVco-D Technique.
Marjanowska A, Wiśniewski K, Póciennik P, et al. · Materials (Basel) 2025
- A novel neuroprotective method against ischemic stroke by accelerating the drainage of brain interstitial fluid.
Lian J, Yang L, Tan H, et al. · Sci China Life Sci 2024
- Investigation of the Effect of the Passivation on the Charge Transfer from MAPbI3 to Electron Transport Layer Using a Heterodyne Transient Grating Spectroscopic Technique.
Jeong SH, Choi SH, Kim YH, et al. · Chemphyschem 2024
- 5-Methoxy-2-aminoindane Reverses Diet-Induced Obesity and Improves Metabolic Parameters in Mice: A Potential New Class of Antiobesity Therapeutics.
Baraghithy S, Gammal A, Permyakova A, et al. · ACS Pharmacol Transl Sci 2024
Also in development for Alcohol Use Disorder
- BrenipatideLY3537031Phase 313 trials
Eli Lilly · Alcohol Use Disorder, Irritable Bowel Syndrome, Depressive Disorder, Major
- MazdutideLY3305677Phase 35 trials
Eli Lilly · Type 2 Diabetes, Obesity, Overweight
- SunobinopV117957Phase 22 trials
Knoa Pharma LLC · Alcohol Use Disorder
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.